I Holland Unveils its New Punch Polisher
I Holland will be launching the innovative MF80 this autumn. The MF80 is an automated punch polisher that offers a large capacity for increased polishing per cycle.
MF80, a new larger capacity version of the recently launch MF40, was designed to help increase polishing capacity. With an 80-L drum and the ability to hold up to 17 B or 12 D punches per holder, it gives a maximum of 85 B or 60 D punches per polishing cycle.
Andy Dumelow PharmaCare Equipment Manager said: "Following the success of the MF40 automated punch polisher, which was launched in 2013, we have now introduced the MF80, which has double the capacity and offers even greater time saving.
The importance of maintaining tools is essential to extending the life of tablet tooling and we recommend using a machine like the MF80 as part of the I Holland 7 Step PharmaCare process, a professional maintenance and storage programme. This procedure follows 7 simple steps to tooling maintenance and includes clean, assess, repair, measure, polish, lubricate and store. The MF80 automated punch polisher ensures consistent, even polishing every time and will help to maximise trouble free tablet production by keeping tooling in perfect condition.
The MF80 can overcome tooling problems such as sticking and corrosion, and will polish dull and discoloured punches to a micro fine high quality finish by using a drag finishing process. The punch is automatically rotated through media and polishing paste, which saves time and ensures a consistent result.
The new automated punch polisher offers a smooth operation, whilst improving efficiency in the tablet press resulting in a quality end product. Operated via touchscreen software and available in several languages, the MF80 will be introduced world-wide.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance